Metsera (MTSR) shareholders voted on Thursday to approve the company’s $10 billion sale to Pfizer (PFE).
The vote came after Pfizer (PFE) won a bidding war with Novo Nordisk (NVO) over the weight-loss drug developer.
Late Friday, New York-based Metsera (MTSR) announced that it reached a revised merger agreement with Pfizer (PFE) to be acquired by the pharma giant for up to $86.25 per share in cash, which it has deemed superior given the evolving antitrust risks of Novo’s (NVO) bid.